Polydeoxyribonucleotide, listed as a single INCI ingredient on cosmetic labels worldwide, can originate from salmon milt, marine microalgae or bacterial fermentation — a sourcing split that determines impurity profiles, traceability records and claim substantiation for every formulation that uses it.

The same-INCI, different-origins problem reads simply on the surface and unravels underneath. PDRN, a polynucleotide chain used in skin-repair and post-procedure formulations, carries one INCI designation across the global register.

A serum, an ampoule or a post-microneedling mask can list "Polydeoxyribonucleotide" without disclosing whether the active came from trout milt, marine microalgae or a ferment-derived route. Each pathway produces a molecule of identical nominal identity but with different molecular weight ranges, endotoxin profiles, residual protein content and chain-of-custody documentation.

What changes for compliance teams?

Regulators reading the front of pack see one ingredient. Compliance teams reading the Certificate of Analysis see something else entirely. The divergence creates two practical problems for anyone running cross-border product launches.

Claim substantiation depends on what sits inside the bottle, not on the label. A brand marketing "salmon-derived PDRN" must hold documentation that traces the material back to its source. Without chain-of-custody records tying declaration to origin, the marketing claim loses its evidentiary anchor in any review by the UK's ASA, the FDA or EU national authorities.

Impurity profiles shift by route. Trout milt-derived material brings characteristic residual proteins and lipid fragments. Biotechnologically produced PDRN carries a different fingerprint, including fermentation by-products. Both can clear general safety assessments, yet neither maps onto a single safety dossier — brands must hold ingredient-grade documentation per supplier, not per INCI.

How does this reshape formulation work?

Formulators increasingly treat PDRN's INCI as a category header, not a specification. The variables that drive performance sit one level deeper:

• Source organism and tissue (trout milt, salmon gonad, microalgae, E. coli fermentation)
• Extraction method (enzymatic, chemical, biotechnological)
• Average molecular weight and polydispersity index
• Endotoxin limit and heavy-metal profile
• Sterilization route (filtration, autoclaving, aseptic processing)

Each variable shifts viscosity behaviour, skin-feel and compatibility with actives such as niacinamide, tranexamic acid or growth-factor mimics. Two PDRNs with identical INCI labels can behave differently in a 5% aqueous gel, a 2% emulsion or a freeze-dried lyophilizate. Texture claims built around "light, fast-absorbing PDRN" will not transfer cleanly between sources.

Why does procurement treat this differently now?

Buyers supplying clinical or post-procedure accounts face the sharpest exposure. Treatment-menu claims — "salmon PDRN delivered via microneedling" — demand documentation a generic CoA cannot provide. Clinics and medical-aesthetic distributors now request full traceability dossiers, not INCI match, before signing annual supply contracts.

Distributors carrying multiple SKUs under one INCI report growing demand for batch-level documentation: country of origin, extraction site, GMP certification of the manufacturing facility, and allergen declarations specific to the source species.

Several Korean and Italian PDRN suppliers have begun publishing this information voluntarily. Others still ship under generic specifications, leaving buyers to close the gap through questionnaires and audits.

What should formulators and brands watch next?

Three signals will define how this category resolves over the next 12-18 months:

• Whether the Personal Care Products Council (PCPC) or the European Commission's CosIng database moves toward disclosure fields for biological origin within the same INCI designation.
• Whether major retail buyers (Sephora, Olive Young Global, Douglas) start requesting origin documentation at the SKU level.
• Whether clinical studies published in the next data cycle differentiate efficacy between salmon-derived and biotechnologically produced material — or treat the category as monolithic.

The trade press has framed PDRN as a single hot ingredient. The supply chain treats it as a portfolio. Brands that bridge the two views with transparent sourcing data will set the benchmark the rest will have to match before any regulator forces the issue.